Predicted to have DEAD/H-box RNA helicase binding activity; DNA-binding transcription activator activity, RNA polymerase II-specific; and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in several processes, including hematopoietic stem cell differentiation; osteoblast differentiation; and positive regulation of stem cell differentiation. Predicted to localize to cytoplasm and nucleus. Human ortholog(s) of this gene implicated in osteogenesis imperfecta type 12. Orthologous to human SP7 (Sp7 transcription factor); INTERACTS WITH 5-formyltetrahydrofolic acid; ammonium chloride; arsenous acid.
[EPO protein co-treated with Glucose] results in increased expression of SP7 mRNA, [EPO protein co-treated with Glucose] results in increased expression of SP7 protein
anacardic acid inhibits the reaction [Tretinoin results in increased expression of SP7 mRNA], ginkgolic acid inhibits the reaction [Tretinoin results in increased expression of SP7 mRNA]
bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SP7 mRNA
[EPO protein co-treated with Glucose] results in increased expression of SP7 mRNA, [EPO protein co-treated with Glucose] results in increased expression of SP7 protein
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA more ...
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA more ...
ethyl protocatechuate inhibits the reaction [Ascorbic Acid results in increased expression of SP7 mRNA], ethyl protocatechuate inhibits the reaction [Ascorbic Acid results in increased expression of SP7 protein]
[EPO protein co-treated with Glucose] results in increased expression of SP7 mRNA, [EPO protein co-treated with Glucose] results in increased expression of SP7 protein
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA more ...
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA more ...
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA more ...
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA more ...
PTH protein promotes the reaction [Vitamin K 2 results in increased expression of SP7 protein], Vitamin K 2 affects the reaction [PTH protein results in increased expression of SP7 protein]
mono-(2-ethylhexyl)phthalate analog results in decreased expression of SP7 mRNA, mono-(2-ethylhexyl)phthalate results in decreased expression of SP7 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of SP7 mRNA], fulvestrant inhibits the reaction [resveratrol results in increased expression of SP7 mRNA]
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein], DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA]
MIR322 mRNA inhibits the reaction [tanshinone results in increased expression of SP7 protein], pyrazolanthrone inhibits the reaction [tanshinone results in increased expression of SP7 protein]
tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in decreased expression of SP7 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
